Physician profile
George Thomas
NPI 1891965299
$8,448.21
in general payments reported to CMS, 2019-2025
13 companies · $7,240 in 2025
The $7,240 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.84 · 2020: $945 · 2022: $93.81 · 2023: $16.54 · 2024: $139 · 2025: $7,240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,630 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,013 · Travel and Lodging: $1,383 · Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,630.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,012.50 |
| Travel and Lodging | $1,383.15 |
| Food and Beverage | $370.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,098.56 | 2019-2025 | Lokelma |
| Corcept Therapeutics | $2,133.84 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $890.50 | 2020 | |
| Medtronic, INC. | $113.78 | 2024 | Symplicity G3 |
| Ascendis Pharma Endocrinology INC | $55.00 | 2025 | Yorvipath |
| Vifor Pharma, INC. | $54.44 | 2022 | |
| Mallinckrodt Hospital Products INC. | $54.20 | 2020 | |
| Akebia Therapeutics INC | $25.32 | 2024 | Vafseo |
| Amgen INC. | $20.08 | 2022 | |
| Travere Therapeutics, INC. | $2.49 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.